Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Overview

Journal J Hepatocell Carcinoma

Date 2023 Jul 17

PMID 37457652

Authors

Meng Tao

Jing Han

Juanyi Shi

Hao Liao

Kai Wen

Weidong Wang

Sintim Mui

Huoming Li

Yongcong Yan

Zhiyu Xiao

Affiliations

Soon will be listed here.

Abstract

Lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), is one of the preferred targeted drugs for the treatment of advanced hepatocellular carcinoma (aHCC). Since the REFLECT study showed that lenvatinib was noninferior to sorafenib in overall survival (OS), lenvatinib monotherapy has been widely used for aHCC. Moreover, lenvatinib combination therapy, especially lenvatinib combined with immune checkpoint inhibitors (ICIs), has shown more encouraging clinical results. However, drug development and comprehensive treatment have not significantly improved the prognosis, and lenvatinib resistance is often encountered in treatment. The underlying molecular mechanism of lenvatinib resistance is still unclear, and studies to solve drug resistance are ongoing. The molecular mechanisms of lenvatinib resistance in patients with aHCC include the regulation of signaling pathways, the regulation of noncoding RNAs, the impact of the immune microenvironment, tumor stem cell activation and other mechanisms. This review aims to (1) summarize the progress of lenvatinib in treating aHCC, (2) delineate the known lenvatinib resistance mechanisms of current therapy, and (3) describe the development of therapeutic methods intended to overcome these resistance mechanisms.

Citing Articles

Mesenchymal Stem Cell-Derived Exosomes in Cancer Resistance Against Therapeutics.

Easwaran V, Pai K, Pai K Cancers (Basel). 2025; 17(5).

PMID: 40075675 PMC: 11898417. DOI: 10.3390/cancers17050831.

SOX11 exacerbates ferroptosis to reduce lenvatinib resistance in liver cancer cells by promoting ubiquitination degradation of SREBF1 through upregulating UBE3A.

Chen Z, Ou L, Ma L Mol Cell Biochem. 2025; .

PMID: 40025300 DOI: 10.1007/s11010-025-05218-x.

Machine learning based ultrasomics noninvasive predicting EGFR expression status in hepatocellular carcinoma patients.

Ma Y, Duan S, Ren S, Bu D, Li Y, Cai X Front Med (Lausanne). 2024; 11:1483291.

PMID: 39624043 PMC: 11609927. DOI: 10.3389/fmed.2024.1483291.

Hepatitis B Virus-Induced Resistance to Sorafenib and Lenvatinib in Hepatocellular Carcinoma Cells: Implications for Cell Viability and Signaling Pathways.

Esmael N, Lubin I, Tur-Kaspa R, Zemel R Cancers (Basel). 2024; 16(22).

PMID: 39594719 PMC: 11592932. DOI: 10.3390/cancers16223763.

Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study.

Tang S, Gao Y, Yan X, Zhi W, Han Y Front Oncol. 2024; 14:1431069.

PMID: 39035736 PMC: 11257876. DOI: 10.3389/fonc.2024.1431069.

References

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

Xie D, Ren Z, Zhou J, Fan J, Gao Q . 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020; 9(4):452-463. PMC: 7423548. DOI: 10.21037/hbsn-20-480. View

Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M . Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Target Oncol. 2022; 17(6):643-653. PMC: 9684293. DOI: 10.1007/s11523-022-00921-x. View

He M, Liang R, Zhao Y, Xu Y, Chen H, Zhou Y . Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021; 13:17588359211002720. PMC: 8010824. DOI: 10.1177/17588359211002720. View

Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K . Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019; 14(2):e0212513. PMC: 6392299. DOI: 10.1371/journal.pone.0212513. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Zhou T, Wang X, Cao Y, Yang L, Wang Z, Ma A . Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res. 2022; 22(1):1367. PMC: 9673291. DOI: 10.1186/s12913-022-08661-4. View

Arighi E, Borrello M, Sariola H . RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005; 16(4-5):441-67. DOI: 10.1016/j.cytogfr.2005.05.010. View

10.

Guo J, Zhu P, Ye Z, Wang M, Yang H, Huang S . YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. Front Pharmacol. 2021; 12:744578. PMC: 8517968. DOI: 10.3389/fphar.2021.744578. View

11.

Wang Y, Liu D, Zhang T, Xia L . FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers (Basel). 2021; 13(6). PMC: 8002748. DOI: 10.3390/cancers13061360. View

12.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View

13.

Mok E, Leung C, Zhou L, Lei M, Leung H, Tong M . Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma. Cancer Res. 2022; 82(17):3102-3115. DOI: 10.1158/0008-5472.CAN-21-2934. View

14.

Qu W, Ding Z, Qu X, Tang Z, Zhu G, Fu X . Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022; 6(5). PMC: 9499852. DOI: 10.1093/bjsopen/zrac114. View

15.

Mo D, Luo P, Huang S, Wang H, Huang J . Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Int Immunopharmacol. 2020; 91:107281. DOI: 10.1016/j.intimp.2020.107281. View

16.

Donne R, Lujambio A . The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2022; 77(5):1773-1796. PMC: 9941399. DOI: 10.1002/hep.32740. View

17.

Sun D, Liu J, Wang Y, Dong J . Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Front Oncol. 2022; 12:944537. PMC: 9496645. DOI: 10.3389/fonc.2022.944537. View

18.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

19.

Li X, Fu Z, Chen X, Cao K, Zhong J, Liu L . Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Front Oncol. 2022; 12:950266. PMC: 9289205. DOI: 10.3389/fonc.2022.950266. View

20.

Garcia-Lezana T, Lopez-Canovas J, Villanueva A . Signaling pathways in hepatocellular carcinoma. Adv Cancer Res. 2021; 149:63-101. DOI: 10.1016/bs.acr.2020.10.002. View